BiotechTube

Azer-cel + Fludarabine + Cyclophosphamide + IL-2

Phase 1Recruiting
0 watching 0 views this week๐Ÿ’ค Quiet
25
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Hodgkin Lymphoma

Conditions

Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Trial Timeline

Mar 11, 2019 โ†’ Jun 1, 2027

NCT ID
NCT03666000

About Azer-cel + Fludarabine + Cyclophosphamide + IL-2

Azer-cel + Fludarabine + Cyclophosphamide + IL-2 is a phase 1 stage product being developed by Imugene for Non-Hodgkin Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03666000. Target conditions include Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03666000Phase 1Recruiting

Competing Products

20 competing products in Non-Hodgkin Lymphoma

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
52
TazemetostatEisaiPhase 2
52
ONTAKEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
ME-401Kyowa KirinPhase 1
33
ME-401Kyowa KirinPhase 2
52
ONO-7018 + ONO-7018Ono PharmaceuticalPhase 1
33
gemcitabineEli LillyPhase 2
52
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
52
LY4152199 - IVEli LillyPhase 1
33
LY317615Eli LillyPhase 2
52
LY4584180 + RituximabEli LillyPhase 1
33
PirtobrutinibEli LillyPhase 2
52
Palbociclib + Sunitinib + Temsirolimus + Trastuzumab and Pertuzumab + Vemurafenib and Cobimetinib + Regorafenib + Olaparib + Nivolumab and Ipilimumab + Abemaciclib + Talazoparib + Atezolizumab and Talazoparib + Tucatinib plus Trastuzumab Subcutaneous (SC) + Futibatinib + Dabrafenib plus Trametinib + Fam-Trastuzumab Deruxtecan-Nxki (TDxD)Eli LillyPhase 2
52
Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
77
HRS-3738Jiangsu Hengrui MedicinePhase 1
33
SHR1459 ๏ผ›YY-20394 + SHR1459 ๏ผ›YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
52
azacitadine + venetoclax + rituximab / IDEC-C2B8 + rituximab / IDEC-C2B8AbbViePhase 1/2
41
Epcoritamab + Cyclophosphamide + Rituximab + Doxorubicin + Vincristine + Prednisone + LenalidomideAbbViePhase 1/2
41
Siltuximab + EpcoritamabAbbViePhase 1
33

Other Products from Imugene

IMU-131 + Ramucirumab plus Paclitaxel + PembrolizumabPhase 2
44
IMU-131 + Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.Phase 1/2
33
CF33-CD19 IT Monotherapy + CF33-CD19 IV Monotherapy + CF33-CD19 IT Combination + CF33-CD19 IV Combination + Blinatumomab + HydroxyureaPhase 1
25
Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 AntibodyPhase 1
25
CF33-hNIS + Pembrolizumab + Modified FOLFOXPhase 1
25